Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinosylvin is a natural stilbenoid polyphenol, specifically a trans-stilbene derivative, primarily found in the heartwood of pine trees such as *Pinus sylvestris* and in certain other woody plants[1][2][4][6][9]. It serves as a pre-infectious toxin and phytoalexin in plants, providing defense against pathogens and insects. Pharmacologically, pinosylvin has been shown to exert **anti-inflammatory, antioxidant, antifungal, antibacterial, anticancer, neuroprotective, and anti-allergic** effects[1][3][5][7]. Mechanistically, it modulates multiple signaling pathways, including inhibition of prostaglandin E2 (PGE2) via COX-2 suppression, inhibition of iNOS and NO production, modulation of the PI3K/Akt and JAK/STAT pathways, and upregulation of heme oxygenase-1 (HO-1) expression involved in cellular antioxidant defense[1][3]. It also affects cell cycle progression, apoptosis (through caspase-3 activation), autophagy (via AMPK activation), and inflammation (through downregulation of pro-inflammatory cytokines such as IL-6 and MCP1)[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pinosylvin.